Here, we extended our study to examine the therapeutic efficacy of PIP-18 on a clinically relevant TNF-driven transgenic mouse model of human RA [16], and to study the possible mechanism of peptide inhibition of the inflammatory pathway in human RA SF. The gene discussed is TNF; the disease is rheumatoid arthritis.